Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

6006 - Nab-paclitaxel (nab-P) in mEtastatic bREast cancer (MBC) In elDerly patiEnts: a real life setting - NEREIDE Study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy;  Geriatric Oncology;  Breast Cancer

Presenters

Vincenzo Adamo

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

V. Adamo1, G.R.R. Ricciardi1, S. Schifano1, A. Russo2, V. Gebbia3, L. Blasi4, D. Giuffrida5, G. Scandurra6, A. Savarino7, A. Butera8, N. Borsellino9, F. Verderame10, M. Caruso11

Author affiliations

  • 1 Department Of Human Pathology University Of Messina, Medical Oncology Unit A.O. Papardo, 98158 - Messina/IT
  • 2 Department Of Surgical, Oncological, And Oral Sciences, Section of Medical Oncology, University of Palermo, 90127 - Palermo/IT
  • 3 La Maddalena Clinic For Cancer, Medical Oncology Unit, 90100 - Palermo/IT
  • 4 Arnas Civico, Medical Oncology Unit, 90015 - Palermo/IT
  • 5 Instituto Oncologico Del Mediterraneo, Medical Oncology Unit, 95029 - Viagrande/IT
  • 6 Cannizzaro Hospital, Medical Oncology Unit, 95121 - Catania/IT
  • 7 Ospedale Barone Lombardo-presidio Ospedaliero Canicattì, Medical Oncology Unit, 92024 - Canicattì/IT
  • 8 Azienda Ospedaliera St. Giovannino Di Dio, Medical Oncology Unit, 92100 - Agrigento/IT
  • 9 Buccheri La Ferla Fatebenefratelli Hospital, Medical Oncology Unit, 90144 - Palermo/IT
  • 10 Cervello Hospital, Medical Oncology Unit, 90146 - Palermo/IT
  • 11 Medical Oncology Unit, Humanitas Centro Catanese di Oncologia, 95121 - Catania/IT
More

Resources

Abstract 6006

Background

Elderly patients (pts) with MBC are under-represented in clinical studies and treatment is largely based on limited retrospective subgroup analyses. However, the 3 ESO-ESMO guidelines for Advanced Breast Cancer suggest that the management decisions should not be based on age alone.

Methods

This is an observational, retrospective, multicenter study conducted in 11 Oncology Sicilian Centers that evaluated safety and efficacy of nab-P in pts with HER2 negative MBC with age ≥ 65 years. We included 70 pts. Intrinsic molecular subtype: Luminal A (18.8%), Luminal B HER-2 negative (62.5%) and Triple negative (18.8%). The most common metastatic sites were: visceral plus bone (31.4%), bone (15.7%), lung (10%), visceral plus lymph nodes (10%). 33% of pts received nab-P as 4th line treatment. 87.1% of all pts received nab-P at doses 260 mg/m23-weekly and 12.9% received nab-P 125 mg/m2weekly. 28.6%, 25.7% and 26.2% of pts received previous treatment with taxanes in the neo-adjuvant and metastatic setting, respectively. Primary endpoint was safety of nab-P treatment. Secondary endpoints were overall response rate (ORR), progression free survival (PFS) and overall survival (OS).PFS and OS curves were estimated using the Kaplan-Meier method. ORR was defined as complete or partial response (CR+PR) according to RECIST 1.1 criteria. Adverse events (AEs) were assessed according to CTCAEv4.0.

Results

Median (m) age of pts who received nab-P: 67 years (65-83). mECOG PS: 1 (range 0-2). The m cycles administrated was 6 (range 1-21). 35.5% of pts had a dose reduction and 11.5% of pts had treatment interruptions due to toxicity. The most frequent AEs were G2-3 and were observed in 47% of pts. The main toxicities were fatigue (61.5%), neuropathy (53.8%) and leukopenia (39.1%) and occurred in the 85.7% of pts treated with 3-weekly nab-P. ORR was 31.3% (CR in 6.3% and PR in 25% of pts). 39.1% of pts reported a stable disease. mPFS was 6 months (95% CI 2-38) and mOS was 40.5 months (95% CI 7-255).

Conclusions

Our real-life study showed that the treatment with nab-P is an effective and well-tolerated regimen in MBC elderly pts, even if previously treated with other taxanes. In particular, our data indicate that the weekly nab-P can be safely administered in elderly MBC pts.

Clinical trial identification

Legal entity responsible for the study

Vincenzo Adamo.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.